Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor

Qing-Hui Zhou, Rachita Sumbria, Eric Ka-Wai Hui, Jeff Zhiqiang Lu, Ruben J. Boado, and William M. Pardridge

Department of Medicine (Q.-H.Z., R.S., R.J.B., W.M.P.), University of California, Los Angeles, California; and ArmaGen Technologies, Inc. (E.K.-W.H., J.Z.L., R.J.B.) Santa Monica, California

Received July 7, 2011; accepted August 9, 2011

ABSTRACT

Biologic tumor necrosis factor (TNF)-α inhibitors do not cross the blood-brain barrier (BBB). A BBB-penetrating TNF-α inhibitor was engineered by fusion of the extracellular domain of the type II human TNF receptor (TNFR) to the carboxyl terminus of the heavy chain of a mouse/rat chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), and this fusion protein is designated cTfRMAb-TNFR. The cTfRMAb-TNFR fusion protein and etanercept bound human TNF-α with high affinity and K_d values of 374 ± 77 and 280 ± 80 pM, respectively. Neuroprotection in brain in vivo after intravenous administration of the fusion protein was examined in a mouse model of Parkinson’s disease. Mice were also treated with saline or a non-BBB-penetrating TNF decoy receptor, etanercept. After intracerebral injection of the nigral-striatal toxin, 6-hydroxydopamine, mice were treated every other day for 3 weeks. Treatment with the cTfRMAb-TNFR fusion protein caused an 83% decrease in apomorphine-induced rotation, a 67% decrease in amphetamine-induced rotation, a 82% increase in vibrissae-elicited forelimb placing, and a 130% increase in striatal tyrosine hydroxylase (TH) enzyme activity. In contrast, chronic treatment with etanercept, which does not cross the BBB, had no effect on neurobehavior or striatal TH enzyme activity. A bridging enzyme-linked immunosorbent assay specific for the cTfRMAb-TNFR fusion protein showed that the immune response generated in the mice was low titer. In conclusion, a biologic TNF inhibitor is neuroprotective after intravenous administration in a mouse model of neurodegeneration, providing that the TNF decoy receptor is reengineered to cross the BBB.

Introduction

Tumor necrosis factor (TNF)-α is a proinflammatory cytokine in peripheral tissues, and the leading TNF-α-inhibitors (TNFIs) are biologic drugs, including etanercept, a TNF decoy receptor-Fc fusion protein, infliximab, a chimeric anti-TNF-α monoclonal antibody (MAb), and adalimumab, a human anti-TNF-α MAb (Tansey and Szymkowski, 2009). TNF-α also plays a pathologic role in brain disorders, including Parkinson’s disease (PD) (McCoy et al., 2006), Alzheimer’s disease (He et al., 2007), and depression (Himmerich et al., 2008). However, the biologic TNFIs cannot be developed for treatment of the brain, because these large molecule drugs do not cross the blood-brain barrier (BBB). Biologic TNFIs can be reengineered for BBB penetration by engineering fusion proteins of the TNFI and a BBB molecular Trojan horse (MTH) (Pardridge, 2010). The latter is a peptide or peptidomimetic MAb that traverses the BBB via transport on an endogenous receptor-mediated transport system, such as the insulin receptor or the transferrin receptor (TfR). The most potent BBB MTH is a genetically engineered MAb against the human insulin receptor (HIR) (Boado et al., 2007). A fusion protein of the HIRMAb and the extracellular domain (ECD) of the type II TNF receptor (TNFR) has been engineered and is designated the HIRMAb-TNFR fusion protein (Hui et al., 2009). The brain uptake of the HIRMAb-TNFR fusion protein in the rhesus monkey is high, >3% of injected dose (ID)/brain, whereas etanercept does not cross the BBB in vivo (Boado et al., 2010). However, the HIRMAb only cross-reacts with the insulin receptor of the Old World ABBREVIATIONS: TNF, tumor necrosis factor; TNFI, tumor necrosis inhibitor; MAb, monoclonal antibody; PD, Parkinson’s disease; BBB, blood-brain barrier; MTH, molecular Trojan horse; TfR, transferrin receptor; HIR, human insulin receptor; ECD, extracellular domain; TNFR, tumor necrosis factor receptor; ID, injected dose; cTfRMAb, chimeric MAb against mouse TfR; TH, tyrosine hydroxylase; ELISA, enzyme-linked immunosorbent assay; CHO, Chinese hamster ovary; ANOVA, analysis of variance; AD, Alzheimer’s disease; PBS, phosphate-buffered saline; PBSB, PBS containing 1% bovine serum albumin.
primate, such as the rhesus monkey (Pardridge et al., 1995), and does not cross-react with the insulin receptor of New World primates or lower animals. There is no known MAb against the mouse insulin receptor that can be used as a BBA MTH in the mouse. Therefore, a surrogate MTH for the mouse has been engineered, which is a chimeric MAB against the mouse TIR, designated the cTIRMAb (Boado et al., 2009). A fusion protein of the cTIRMAb and the ECD of the TNFR-II has been engineered (Zhou et al., 2011a), and the structure of the cTIRMAb-TNFR fusion protein is shown in Fig. 1A. The decoy receptor is fused to the carboxyl terminus of the heavy chain of the IgG part of the fusion protein. In contrast, for the engineering of etanercept (Peppel et al., 1991), the TNFR decoy receptor is fused to the amino terminus of the heavy chain of the Fe fragment (Fig. 1B).

The present investigation tests the neuroprotective actions of both the cTIRMAb-TNFR fusion protein and etanercept in the 6-hydroxydopamine mouse model of PD. The fusion proteins are administered every other day over a 3-week period by intravenous injection in the tail vein. Neuroprotection is assessed with three assays of neurobehavior, with a striatal tyrosine hydroxylase (TH) enzyme activity, and with TH immunocytochemistry. The level of immune response in mice caused by chronic administration of the cTIRMAb-TNFR fusion protein is assessed with a bridging ELISA.

Materials and Methods

Mouse Parkinson’s Disease Model and Treatment. All procedures were approved by the UCLA Animal Research Committee. Adult male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) weighing 25 to 32 g were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) intraperitoneally. Animals received a unilateral intracerebral injection of a total of 12 μg of 6-hydroxydopamine HBr (Sigma-Aldrich, St. Louis, MO) dissolved in saline (n = 10 mice); etanercept, 1.0 mg/kg (n = 10 mice); or the cTIRMAb-TNFR fusion protein, 1.0 mg/kg (n = 10 mice), every 2 days over the following 3 weeks, with the first dose given 1 h after toxin injection into the brain. Treatment drugs were injected intravenously via the tail vein in a volume of 50 μl/mouse. The mice were euthanized at 3 weeks after toxin administration for measurement of striatal TH enzyme activity.

Etanercept (Enbrel) was obtained from the UCLA Pharmacy. The cTIRMAb-TNFR fusion protein was purified by protein G affinity chromatography of serum-free medium conditioned by stably transfected Chinese hamster ovary (CHO) cells as described previously (Zhou et al., 2011a). The 235-amino-acid extracellular domain of the type II human TNFR, minus the signal peptide, was fused to the carboxyl terminus of the heavy chain of the cTIRMAbs (Fig. 1A) as described previously (Zhou et al., 2011a). The fusion protein was formulated in 0.01 M sodium acetate-buffered saline (pH 6.5) and was stored either sterile-filtered at 4°C or at −70°C. The molecular mass of the cTIRMAb-TNFR fusion protein is 195,200 Da (Zhou et al., 2011a), whereas the molecular mass of etanercept is 51,200 Da. Therefore, at a systemic dose of each fusion protein of 1 mg/kg, a nearly 4-fold molar excess of etanercept was administered.

TNF-α Radioreceptor Assay. The saturable binding of human TNF-α to either etanercept or to the cTIRMAb-TNFR fusion protein was determined with a radioreceptor assay as described previously (Hui et al., 2009). For TNF-α binding to either the cTIRMAb-TNFR fusion protein or to a mouse IgG1 negative control, a goat anti-mouse IgG1Fc antibody (Bethyl Laboratories, Montgomery, TX) was plated in 96-well plates (0.2 μg/well). For TNF-α binding to either etanercept or to a human IgG1 negative control, a mouse anti-human IgG1Fc antibody (Invitrogen, Carlsbad, CA) was plated in 96-well plates (0.2 μg/well). The fusion protein or negative control antibody was plated (100 ng/well), followed by a 1-h incubation at room temperature. The wells were then washed with phosphate-buffered saline (PBS), followed by the addition of 100 μl/well of a comixture of [3H]human TNF-α (specific activity = 91 μCi/μg; PerkinElmer Life and Analytical Sciences, Waltham, MA) at a concentration of 0.01 μCi/well (0.1 μCi/ml; 1.1 ng/ml; 60 pM) and various concentrations of unlabeled human TNF-α, followed by a 3-h incubation at room temperature. The wells were washed, and bound radioactivity was determined with a radiodensity assay as described previously (Hui et al., 2009). The half-saturation constant, Kd, of TNF-α binding to the cTIRMAb-TNFR or etanercept fusion protein was determined by nonlinear regression analysis using BMDP2007e software (Statistical Solutions, Cork, Ireland), after fitting of binding data to the following equation: bound = (Bmax × [C]/(Kd + C)), where Bmax is the maximal binding and C is the concentration of TNF-α.

Behavioral Testing. Beginning 1 week after the toxin administration, mice were tested weekly for apomorphine- and amphetamine-induced rotation, which was performed on separate days, as described previously (Fu et al., 2010). A vibrisse-elicted forelimb-placing trial in the mice was performed at the end of the 3 weeks of treatment (Fu et al., 2010).

Tyrosine Hydroxylase Enzyme Activity. Homogenates of mouse brain striatum (left and right side) and frontal cortex were prepared with a Polytron homogenizer in 5 mM KPO4-0.1% Triton X-100 (pH 6.3) followed by centrifugation. After an aliquot was removed for measurement of protein with the bicinchoninic acid assay, dithiothreitol was added to the supernatant to 1 mM, and the supernatant was stored at −70°C until assay. The TH enzyme activity in the supernatant was measured with [3,5,4H]-tyrosine (PerkinElmer Life and Analytical Sciences) as substrate. The purity of the [3,5,4H]-tyrosine was assessed by thin-layer chromatography. TH enzyme activity converts [3,5,4H]-tyrosine to L-DOPA and [4H]water. The [4H]water product was separated from the [3H]tyrosine substrate with a charcoal separation technique, as described previously (Fu et al., 2010). Any residual [4H]water present in the [3,5,4H]-tyrosine was accounted for with determinations of assay blanks in each assay. The assay was validated with [4H]water (PerkinElmer Life and Analytical Sciences), which showed that the

---

**Fig. 1.** A, the cTIRMAb-TNFR fusion protein is formed by fusion of the ECD of the type II human TNFR to the carboxyl terminus of each heavy chain of the cTIRMAb. B, the etanercept fusion protein is formed by fusion of the same ECD of the type II human TNFR to the amino terminus of the Fe fragment of human IgG1 heavy chain.
radioreceptor assay shows saturation of binding of human TNF-α to either the cTRMAB-TNFR fusion protein or to etanercept. The binding dissociation constant, \( K_D \), was determined by nonlinear regression analysis. The horizontal line at 1.5% binding represents the nonspecific binding observed when either human IgG1 or mouse IgG1 was plated in lieu of the fusion protein.

\[ \text{[\text{H}]water} \text{ was 100\% recovered in the supernatant after removal of amino acid by the charcoal. TH enzyme activity was measured at 37°C for 30 min and is expressed as picomoles per hour per milligram of protein.} \]

**Tyrosine Hydroxylase Immunocytochemistry.** The brain was removed and coronal blocks were frozen in powdered dry ice, followed by embedding in Tissue Tek OCT medium, and refrozen, and blocks were stored at −70°C. Frozen sections (20-μm thickness) were prepared at −20°C on a Micron Instruments (San Marcos, CA) cryostat. Sections were fixed in ice-cold acetone-methanol (1:1) at −20°C for 20 min. Immune staining was performed with an affinity-purified rabbit antibody against rat TH, which cross-reacts with all forms of mammalian TH (Pel-Freez, Rogers, AR), which was diluted 1:1000 in PBS with 0.3% Triton X-100 and 3% horse serum. The secondary antibody was 2 μg/ml biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA). Immune detection was performed with the ImmPACT DAB kit (Vector Laboratories) using diaminobenzidine. The sections were not counterstained and were scanned with a UMAX PowerLook III scanner with transparency adapter. Striatal immunostaining on the lesioned and nonlesioned side was quantitated by determination of optical density using Image software (version 1.62; National Institutes of Health, Bethesda, MD). The entire striatum on both the lesioned and nonlesioned side was outlined for measurement of density of staining. In addition, the cortex was outlined as a measure of the background, and the cortical density was subtracted from the striatal density to yield the background-corrected density of striatal immunostaining.

**Immunity ELISA.** The presence of anti-cTRMAB-TNFR fusion protein antibodies in mouse plasma was measured with a two-site sandwich ELISA described previously (Zhou et al., 2011b). The cTRMAB-TNFR fusion protein is used as the capture reagent, and biotinylated cTRMAB-TNFR fusion protein is used as the detector reagent. The mouse plasma was diluted 1:50 in PBS. The capture reagent was plated overnight at 4°C in 96-well plates at 100 μl (250 ng/well) in 0.05 M NaHCO3/pH 8.3. The wells were blocked with PBS containing 1% bovine serum albumin (PBSB), followed by the addition of 100 μl/well of a 1:50 dilution of mouse plasma. After a 60-min incubation at 37°C, the wells were washed with PBSB, and the wells were incubated with biotinylated cTRMAB-TNFR fusion protein (25 ng/well) for 60 min. The wells were washed with PBSB, followed by incubation with 100 μl (500 ng/well) of a streptavidin-peroxidase conjugate (Vector Laboratories) for 30 min at room temperature. The wells were washed with PBSB, and 100 μl/well o-phenylenediamine-H2O2 developing solution (Sigma-Aldrich) was added for a 15-min incubation in the dark at room temperature. The reaction was stopped by the addition of 100 μl/well 1 M HCl, followed by the measurement of absorbance at 492 and 650 nm. The \( A_{492} \) was subtracted from the \( A_{650} \). The \( (A_{492} - A_{650}) \) for the PBSB blank was then subtracted from the \( (A_{492} - A_{650}) \) for the sample.

The cTRMAB-TNFR fusion protein was biotinylated with sulfo-biotin-LC-LC-N-hydroxysuccinimide, where LC = long-chain (Pierce Chemical). The biotinylation of the cTRMAB-TNFR fusion protein was confirmed by SDS-polyacrylamide gel electrophoresis and Western blotting, for which the blot was probed with avidin and biotinylated peroxidase. The nonbiotinylated cTRMAB-TNFR fusion protein was tested as a negative control.

**Statistical Analysis.** Statistical differences between saline-, etanercept-, and fusion protein-treated mice were determined with analysis of variance (ANOVA) with Bonferroni correction. Statistical differences between striatal immunostaining on the lesioned and nonlesioned side were determined with Student’s t test.

**Results**

TNFα bound to both the cTRMAB-TNFR fusion protein and to etanercept with high affinity and \( K_D \) values of 374 ± 77 and 280 ± 80 pm, respectively (Fig. 2).

Mice tolerated the chronic treatment with either etanercept or the cTRMAB-TNFR fusion protein, no mice exhibited signs of immune reaction to the study drugs, and no weight loss was observed in any of the treatment groups. Treatment of PD mice with chronic intravenous cTRMAB-TNFR fusion protein resulted in a 75 to 83% reduction in amphetamine-induced rotation compared with that in saline-treated mice, whereas etanercept had no significant effect on drug-induced rotation (Fig. 3). Treatment of PD mice with chronic intravenous cTRMAB-TNFR fusion protein caused a 45 to 67% reduction in amphetamine-induced rotation compared with that in saline-treated mice, whereas etanercept had no significant effect on drug-induced rotation (Fig. 4).

Treatment of PD mice with chronic intravenous cTRMAB-TNFR fusion protein caused a 82% increase in the vibrissa-elicited forelimb placing score compared with that for the saline-treated mice, whereas etanercept had no significant effect on forelimb placing (Fig. 5).

Treatment of PD mice with chronic cTRMAB-TNFR fusion protein caused a 130% increase in striatal TH enzyme activity on the lesioned (right) side, relative to that in saline-treated mice, whereas etanercept had no significant effect on striatal TH enzyme activity (Fig. 6).
Chronic treatment with the cTfRMAb-TNFR fusion protein had no effect on TH enzyme activity in either the frontal cortex or the striatum on the nonlesioned (left) side (Fig. 6). The TH enzyme activity results were corroborated with TH immunocytochemistry, which shows the TH immunoreactivity in the striatum on the lesioned and nonlesioned side for three mice treated with the cTfRMAb-TNFR fusion protein (Fig. 7, A–C) and for three mice treated with saline (Fig. 7, D–F). The density of the striatal TH immunostaining on the lesioned side was increased 101% in the mice treated with the cTfRMAb-TNFR fusion protein compared with the saline-treated mice (Table 1).

The design of the immunity ELISA is shown in Fig. 8A. The detector reagent is biotinylated cTfRMAb-TNFR fusion protein, and biotinylation of the fusion protein is verified by Western blot analysis (Fig. 8B). The preinjection mouse plasma and the terminal plasma from the etanercept-treated mice produced no immune reaction with cTfRMAb-TNFR fusion protein (Fig. 8C). There was a variable immune reaction observed at the end of the study in the mice treated with the cTfRMAb-TNFR fusion protein at 1:50 dilutions of plasma (Fig. 8C).

**Discussion**

The results of this study are consistent with the following conclusions. First, the cTfRMAb-TNFR fusion protein and the TNFR-Fc fusion protein (etanercept) have comparable affinity of binding of TNFα, with a low a $K_D$ of 1 nM (Fig. 2). Second, chronic intravenous treatment of mice with experimental PD with the cTfRMAb-TNFR fusion protein results in neuroprotection, based on three assays of neurobehavior (Figs. 3–5), striatal TH enzyme activity (Fig. 6), and striatal TH immunocytochemistry (Fig. 7; Table 1). Third, chronic intravenous treatment with a comparable dose of the TNFR-Fc fusion protein (etanercept) has no therapeutic ef-

---

**Fig. 4.** Ipsilateral rotation (over 20 min) after the administration of amphetamine to PD mice treated with saline, etanercept, or the cTfRMAb-TNFR fusion protein at 1, 2, and 3 weeks after toxin injection. Data are means ± S.E. ($n = 10$ mice/group). Statistical differences from the saline-treated animals: *, $p < 0.01$; †, $p < 0.05$, at weeks 1, 2, and 3, as determined by ANOVA with Bonferroni correction.

**Fig. 5.** Vibrissae-elicited forelimb placing test scores for the right side, which is ipsilateral to the toxin lesion, and for the left side, which is contralateral to the toxin lesion, for the saline-, etanercept-, and the cTfRMAb-TNFR fusion protein-treated mice. All scores were measured at 3 weeks after toxin injection. Data are means ± S.E. ($n = 10$ mice/group). Statistical differences from the saline-treated animals: *, $p < 0.01$, as determined by ANOVA with Bonferroni correction.

**Fig. 6.** TH enzyme activity on the lesioned side (right) and the nonlesioned side (left) in the striatum and in the frontal cortex of mice treated with saline, etanercept, or the cTfRMAb-TNFR fusion protein. Brain TH activity was measured at 3 weeks after toxin administration. Data are means ± S.E. ($n = 10$ mice/group). Statistical differences from the saline-treated animals in the right striatum: *, $p < 0.01$, as determined by ANOVA with Bonferroni correction.

**Fig. 7.** TH immunocytochemistry for three mice treated with the cTfRMAb-TNFR fusion protein (A–C) and three mice treated with saline (D–F). The lesioned side of the brain corresponds to the right side of the figure.
Because the cerebral concentration of TNF-α in mice is high and is comparable to the binding affinity of etanercept (Fig. 1B). The engineering of the cTfRMAb-TNFR fusion protein is low-titer and produces no immune response (Fig. 8). This finding suggests that the immune response is directed against the cTfRMAb part of the antibody. However, the immune response against the cTfRMAb-TNFR fusion protein is low-titer and produces an average optical density reading of 0.2 with a 1:50 dilution of plasma taken preinjection or postinjection after 3 weeks of either intravenous injections with either etanercept or the cTfRMAb-TNFR fusion protein. Data are shown for all 10 mice in each group.

Chronic treatment of PD mice with the cTfRMAb-TNFR fusion protein causes an immune response against the fusion protein, whereas chronic administration of etanercept in mice causes no immune response (Fig. 8). This finding suggests that the immune response is directed against the cTfRMAb part of the antibody. However, the immune response against the cTfRMAb-TNFR fusion protein is low-titer and produces an average optical density reading of 0.2 with a 1:50 dilution of plasma taken preinjection or postinjection after 3 weeks of either intravenous injections with either etanercept or the cTfRMAb-TNFR fusion protein. Data are shown for all 10 mice in each group.

### TABLE 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Density of Striatal Staining ( Absorbance at 1:50 dilutions )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesioned</td>
<td>Nonlesioned</td>
</tr>
<tr>
<td>cTfRMAb-TNFR</td>
<td>0.167 ± 0.028*</td>
</tr>
<tr>
<td>Saline</td>
<td>0.083 ± 0.009</td>
</tr>
</tbody>
</table>

*P < 0.05, difference from saline treatment. Striatal density was corrected for background density over cortex.

---

Chronic treatment of PD mice with intravenous etanercept has no therapeutic effect on neurobehavior (Figs. 3–5) or striatal TH enzyme activity (Fig. 6). The lack of therapeutic effect of intravenous etanercept is consistent with prior work showing that etanercept does not cross the BBB (Boado et al., 2010). Owing to the lack of BBB penetration, it was necessary to administer etanercept by direct injection into the spinal cord in the rat model of spinal cord injury (Marchand et al., 2009). There is evidence for focal BBB disruption in toxin-induced PD, and mice with knockout of the TNFR have less BBB disruption after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration (Zhao et al., 2007). Therefore, treatment of PD mice with the cTfRMAb-TNFR fusion protein would be expected to reduce BBB disruption mediated by TNF-α. However, any disruption of the BBB that occurs in the 6-hydroxydopamine model in the mouse is insufficient to enable brain penetration of a therapeutic agent such as etanercept, because chronic dosing of PD mice with etanercept is not therapeutic (Figs. 3–6).

Chronic dosing of mice with the cTfRMAb-TNFR fusion protein causes an immune response against the fusion protein, whereas chronic administration of etanercept in mice causes no immune response (Fig. 8). This finding suggests that the immune response is directed against the cTfRMAb part of the antibody. However, the immune response against the cTfRMAb-TNFR fusion protein is low-titer and produces an average optical density reading of 0.2 with a 1:50 dilution of plasma taken preinjection or postinjection after 3 weeks of either intravenous injections with either etanercept or the cTfRMAb-TNFR fusion protein. Data are shown for all 10 mice in each group.

---

**Fig. 8.** A, structure of the two-site ELISA for detection of antibodies against the cTfRMAb-TNFR fusion protein. The cTfRMAb-TNFR fusion protein is used as the capture reagent, and the biotinylated cTfRMAb-TNFR fusion protein is used as the detector reagent, along with a complex of streptavidin (SA) and horseradish peroxidase (HRP); the biotin moiety is designated, B. B, Western blot of nonbiotinylated cTfRMAb-TNFR fusion protein (lane 1) and biotinylated cTfRMAb-TNFR fusion protein (lane 2) with a conjugate of avidin and biotinylated peroxidase. C, absorbance at 1:50 dilutions of mouse plasma taken preinjection or postinjection after 3 weeks of either intravenous injections with either etanercept or the cTfRMAb-TNFR fusion protein. Data are shown for all 10 mice in each group.
of 100 μl of plasma (Fig. 8). The low-titer immune response in this study equates to 0.1 optical density/μl plasma. This titer is 100-fold lower than the immune response against biologic drugs that neutralize therapeutic effects of the drug (Dickson et al., 2008). Moreover, recent work has shown that the low-titer immune response produced with chronic treatment with cTfRMAb fusion protein has no neutralizing effect on the TR in vivo (Zhou et al., 2011b). The rate of brain uptake of fusion-protein-treated mice and saline-treated mice is comparable at the end of 12 weeks of twice weekly treatment with 2 mg/kg doses of cTfRMAb fusion protein (Zhou et al., 2011b). The low-titer, non-neutralizing immune response induced by the fusion protein may be related to the presence of specific amino acid sequences within the constant region of the heavy chain that induce T-cell immune tolerance (De Groot et al., 2008). In addition, the fusion protein is produced in CHO cells, which secrete fucosylated glycoproteins, and fucosylated glycoproteins have minimal effects on antibody-dependent cytotoxicity (Kanda et al., 2006). Ectaneous produced in CHO cells is fucosylated and does not induce antibody-dependent cytotoxicity (Shoji-Hosaka et al., 2006).

In summary, neurodegenerative disease of brain has an inflammatory component triggered in part by TNF-α. Central nervous system disease should be treatable with biologic TNF inhibitors similar to the use of these agents for inflammation in peripheral conditions (Tansey and Szymkowski, 2009). However, the biologic TNF inhibitors, such as the TNFR decoy receptor, do not cross the BBB (Boado et al., 2010). Systemic ectaneous administration has no therapeutic effect in the mouse model of PD, and this is attributed to the lack of ectaneous transport across the BBB. However, the same TNF-α decoy receptor that forms ectaneous is therapeutic after intraocular injection in a mouse model of PD, providing that the TNFα decoy receptor is reengineered to cross the BBB. Fusion of the TNF-α decoy receptor to the cTfRMAb, which acts as a BBB molecular Trojan horse, creates a new IgG-TNF fusion protein. The Trojan horse-TNF fusion protein both binds the BBB TR, to enable brain penetration from blood, and binds TNF-α, to inhibit the action of this inflammatory cytokine in brain behind the BBB.

Acknowledgments
Winnie Tai and Phuong Tram provided expert technical assistance.

Authorship Contributions
Participated in research design: Zhou, Sumbria, Hui, Lu, Boado, and Partridge.
Conducted experiments: Zhou, Sumbria, Hui, Lu, and Boado.
Performed data analysis: Zhou, Sumbria, Hui, Lu, Boado, and Partridge.
Wrote or contributed to the writing of the manuscript: Zhou, Sumbria, Hui, Lu, Boado, and Partridge.

References
Boado RJ, Hui EK, Lu JZ, and Partridge WM (2010) Drug targeting of erythropoi-
etin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 333:961–969.
Boado RJ, Zhang Y, Zhang Y, and Partridge WM (2007) Humanization of anti-

Lee LJ, Engelhardt B, Lesley J, Bickel U, and Partridge WM (2000) Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain bar-
Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, and O’Callaghan JP (2000) Mice deficient in TNF receptors are protected against dopaminergic neu-
Tansey MG and Szymkowski DE (2009) The TNF superfamily in 2009: new path-

Address correspondence to: Dr. William M. Partridge, UCLA Warren Hall 13-164, 900 Veteran Ave., Los Angeles, CA 90024. E-mail: wpartridge@mednet.ucla.edu